Immuron licenses Travelan in China region


By Dylan Bushell-Embling
Tuesday, 17 February, 2015


Immuron licenses Travelan in China region

Immuron (ASX:IMC) has signed an agreement with a Chinese distributor to sell its Travelan OTC preventative treatment for traveller’s diarrhoea in China, Hong Kong and Macau.

Linker Holdings has negotiated the exclusive rights to market, sell and distribute Travelan in the region as a functional food and dietary supplement.

The agreement is contingent on Linker securing regulatory approval from the Chinese Food and Drug Administration.

Immuron said Linker has agreed to comply with annual minimum purchase obligations, and even these obligations represent a significant increase in Travelan sales figures, to the extent that it’s measurable in multiples of current volumes.

Immuron chairman Dr Roger Aston said Travelan is currently available in Australia and Canada, but the Chinese market has the potential to eclipse both markets combined in terms of demand.

“China is a large and increasingly wealthy market, in which gut and liver health are important concerns,” he said. “Additionally, the South East Asian cultures’ predisposition to, and appreciation of, the benefits of colostrum strongly positions Travelan in this market.”

Colostrum is the first milk produced by a pregnant mammal - it is naturally rich in antibodies. Immuron derives Travelan from cows that have been immunised with a proprietary vaccine against enterotoxigenic escherichia coli (ETEC).

Immuron (ASX:IMC) shares were trading 12.2% higher at $0.23 as of around 1 pm on Tuesday.

Image credit: ©freeimages.com/profile/knox_x

Related Articles

Ancient DNA rewrites the stories of those preserved at Pompeii

Researchers have used ancient DNA to challenge long-held assumptions about the inhabitants of...

Bright nights may increase risk of death, Alzheimer's

Avoiding night light and seeking daylight may lead to reduction in disease burden, especially...

COVID-19 infection increases risk of heart attack and stroke

COVID-19 infection may increase the risk of heart attack, stroke and death from any cause for up...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd